No Data
Jacobio Pharmaceuticals Completes Dosing for Anti-Cancer Drug Clinical Trial in China
Jaccase (01167) initiated the first clinical study of pan-KRAS inhibitor.
Gilead initiates the first clinical study of pan-KRAS inhibitors.
Jaccoud-B (01167.HK): Goleizase treats pancreatic cancer indications recognized as orphan drug therapies in europe.
On October 21, Gekso-B (01167.HK) announced that the company's independently developed KRAS G12C inhibitor, Glecirasib, has been designated as an orphan drug therapy by the European Medicines Agency for pancreatic cancer. Pancreatic cancer is a highly malignant tumor, with patients currently lacking effective standard treatment options, and a five-year overall survival rate of only 3.1% in advanced pancreatic cancer. Previously, Glecirasib's indication for pancreatic cancer received orphan drug therapy designation from the Food and Drug Administration (FDA) in the USA, and breakthrough therapy designation from the National Medical Products Administration's Center for Drug Evaluation in China.
Express News | Jacobio Pharmaceuticals - Glecirasib for Treatment of Pancreatic Cancer Granted Orphan Drug Designation in Europe
At the 5th RAS Initiative Symposium in 2024, Akeso-B (01167.HK) presented preclinical data on the combination of SHP2 inhibitor JAB-3312 and KRAS G12C inhibitor lorlatinib.
Grain 10 released on October 9th. Acosta-B (01167.HK) announced that the company presented preclinical data on the combined use of SHP2 inhibitor JAB-3312 and KRAS G12C inhibitor Gorarelec inhibitor in the form of a poster at the Fifth RAS Initiative Symposium 2024. The data demonstrates that Gorarelec and JAB-3312 show strong anti-tumor effects in both in vitro and in vivo experiments, with JAB-3312 enhancing the anti-tumor effects of Gorarelec.
Gaxo-B (01167) spent 0.197 million Hong Kong dollars to repurchase 0.1002 million shares on October 8th.
Jardine Matheson Group-B (01167) announced, on October 8, 2024, spending 0.197 million Hong Kong dollars to repurchase 10...
No Data
No Data
